Cofactor Genomics, has launched a new tool called OncoPrism®-NSCLC. The test aims to help doctors predict how well patients with non-small cell lung cancer (NSCLC) might respond to immune checkpoint inhibitors (ICI), a common type of cancer treatment.
The test builds on Cofactor’s earlier success with OncoPrism-HNSCC, a similar diagnostic for head and neck cancer that recently gained Medicare coverage. Both tests use Cofactor’s innovative approach, combining RNA analysis with machine learning, to give doctors more precise insights about how patients might respond to treatment.
Lung cancer is one of the most common cancers treated with ICIs, and the launch of OncoPrism-NSCLC could expand the number of patients who benefit from RNA-based diagnostics.
“NSCLC patients represent the largest group being treated with ICIs, so this test has the potential to make a big impact,” said Dr. Jarret Glasscock, CEO of Cofactor Genomics. “It’s another step forward in helping more cancer patients access personalized treatment options.”
The test uses tumor biopsies taken before treatment to predict whether a patient will respond well to ICIs, either on their own or in combination with chemotherapy. It’s processed in Cofactor’s laboratory, which meets national standards for diagnostic testing. The validation of OncoPrism-NSCLC involved data from patients at 12 clinical sites as part of the PREDAPT trial, with a total of 17 sites contributing to the broader study.
This isn’t the only area Cofactor is exploring. The company’s ongoing PREDAPT clinical trial is also testing the OncoPrism platform in nine other cancers, including colorectal, breast, and liver cancers. These efforts could eventually expand the use of RNA-based diagnostics across a wide range of cancer types.
Cofactor’s work focuses on RNA, which can provide unique insights into how a patient’s body and tumor interact. Instead of looking for individual genetic mutations, its Health Expression Models analyze RNA patterns, offering a broader picture of how a patient might respond to treatment.